health · manufacturing · family: the rulebook was written for a world that no longer exists
stockpiled ventilators that can't ventilate
Stockpile ventilators that can't ventilate: the missing performance standards for emergency preparedness
Problem statement
The COVID-19 pandemic revealed that many ventilators stockpiled in the Strategic National Stockpile and procured under emergency contracts had capabilities "far below" those of the stockpile's own main ventilator, the LTV 1200, which had itself been judged to have important limitations for COVID-19 patients; set beside the portable critical care ventilator the Respiratory Care review uses for comparison, two of the models it tabulates, the pNeuton A-E and SAVe II, have narrower PEEP ranges, fewer ventilation modes, and no monitoring of delivered flow or volume. The FDA's Emergency Use Authorization process authorized ventilators, modified anesthesia gas machines, and modified positive-pressure breathing devices under a single umbrella authorization that refers to them "collectively" as "ventilators"; the authors of the Respiratory Care review, noting that a couple of the ventilators bought for the stockpile appear on the EUA list and neither is identified as a critical care ventilator, urge the FDA to reconsider the definition of a critical care ventilator so that the distinction is clear "even to the uninitiated." The review, which notes that minimum requirements for ventilators used in acute respiratory failure had already been published, describes no binding performance tier standard that differentiates critical care ventilators from transport, home-use, or emergency ventilators by clinical capability.
Why this matters
In a future respiratory pandemic or mass casualty event, the capability gap between stockpiled devices and clinical needs could contribute to preventable deaths. Early in COVID-19, a March 2020 NEJM commentary put the number of ventilators in the United States at 60,000 to 160,000, depending on whether devices with only partial functionality are counted, against estimates of need running "from several hundred thousand to as many as a million"; the Respiratory Care review calls the early predictions "inaccurate and often unrealistic," reports that regional surges and high mortality worked together to avoid a nationwide ventilator shortage, and says rationing of ventilators, though discussed in the lay press and medical literature, was never necessary in the US. What the anticipated shortage did produce was use of suboptimal devices: anesthesia workstations moved into ICU service, which the review says are built to be attended by anesthesia staff for cases under 24 hours, and noninvasive bi-level ventilators of the kind used at home, which it says were not intended for continuous life support, authorized for invasive ventilation.
What’s been tried and why it hasn’t worked
The FDA's EUA list labels each authorized device by type (among them critical care ventilator; ventilator for continuous, minimal ventilatory support; emergency ventilator), but the authorization's criteria for safety, performance and labeling set no minimum capability for any type — no required PEEP range, tidal volume accuracy, FiO2 control, or ventilation modes; sponsors are asked to report their device's modes, parameter ranges, alarms and monitored parameters, and to declare conformance with the listed standards "as applicable." ISO 80601-2-12, the particular standard for critical care ventilators, is on the authorization's list of standards, but sponsors were asked to declare conformance with it only "as applicable to the device." During the pandemic, the FDA issued EUAs that authorized a wide range of devices — modified anesthesia gas machines, home CPAP/BiPAP devices, and emergency transport ventilators — all under the same umbrella authorization, which distinguishes device types by name but not by any performance tier. The 2020 emergency purchases exemplified the deeper structural issue: the federal government set a goal of 200,000 additional ventilators and procured 15 different models, and the review says the groups in charge of purchasing "had no medical expertise, much less ventilator expertise"; by the authors' judgment about half the ventilators purchased are ill-suited for use in critical care, over 70,000 devices in all. The pNeuton A-E and SAVe II, bought in numbers of about 50,000 and 11,000, cost $7,600 and $6,700 apiece against about $20,000 for the Hamilton T1 the review uses as its portable critical care comparison. Post-pandemic, the FDA's EUA page says the public health emergency expired on May 11, 2023, that existing device EUAs remain in effect, and that the declarations behind them are to be terminated effective December 26, 2026. The review's authors write that the lesson that ventilator numbers cannot be separated from critical care capacity "was known before COVID-19, and this is a lesson we should not relearn in the next pandemic."
What would unlock progress
A binding, tiered performance standard — adopted by FDA and referenced by BARDA procurement specifications — that clearly defines minimum clinical capabilities for each ventilator category would ensure stockpiled devices can actually perform the clinical functions required in a crisis. This standard should be paired with procurement specifications that weight clinical capability alongside cost-per-unit, changing the incentive structure that produced the current stockpile gap. Modular ventilator designs that allow capability upgrades (adding modes, monitoring, or precision controls to a base platform) could bridge the cost-capability tradeoff.
Entry points for student teams
A student team could conduct a systematic comparison of currently stockpiled ventilator models against published clinical requirements for ARDS management, producing a gap analysis and proposed performance tier framework. An engineering team could prototype a modular ventilator architecture where a low-cost base unit can be upgraded with snap-in modules for advanced modes (pressure-regulated volume control, high PEEP capability, waveform monitoring) to address the cost-versus-capability tradeoff. A policy-focused team could draft a model procurement specification for state or federal emergency ventilator stockpiles that incorporates clinical capability tiers.
Genes
Structural cousins: stuck the same way, in other fields
Sources
Respiratory Care, "COVID-19 Lessons Learned: Response to the Anticipated Ventilator Shortage," 2023 — accessed 2026-02-19 go to source ↗
Working notes
Notes made while writing and checking this brief, shown as written. They use working shorthand.
Primary sources include the Respiratory Care analysis (2023) documenting stockpile ventilator inadequacies, FDA EUA records for ventilators during COVID-19, and NEJM commentary on critical supply shortages. The "wrong-problem" failure tag reflects that pandemic preparedness procurement solved for "how many ventilators can we buy cheaply" rather than "can these ventilators keep ARDS patients alive." The "window" temporal tag captures the post-pandemic moment: political attention is fading, but the institutional memory and evidence base are still fresh enough to drive regulatory reform before the next crisis. The "ignored-context" tag reflects that clinicians' operational requirements for critical care ventilation were not adequately incorporated into stockpile procurement decisions. Related briefs may include emergency medical device supply chains, point-of-care device design for resource-limited settings, or pandemic preparedness infrastructure.
Reconciliation 2026-09-30: Fact repair after reading the whole write-up against its sources; a second reader went over the repairs on the same day, opened every source again independently, and tightened five of them (noted below). The Source-line paper (Branson RD, Rodriquez D, "COVID-19 Lessons Learned: Response to the Anticipated Ventilator Shortage," Respiratory Care 2023;68(1):129-150) was read in full on 2026-09-30 from its PubMed Central copy, https://pmc.ncbi.nlm.nih.gov/articles/PMC9993519/, including the images of Tables 1 and 2; the publisher page at the DOI returned 403, and the citation was confirmed against the Crossref and Europe PMC records. The two sources named only in these notes were also read: the FDA's "Ventilators and Ventilator Accessories EUAs" page (fetched 2026-09-30, content dated 08/11/2026) together with its Appendix A criteria PDF, read in full; and the NEJM commentary, identified from the paper's reference 15 as Ranney ML, Griffeth V, Jha AK, "Critical Supply Shortages - The Need for Ventilators and Personal Protective Equipment during the Covid-19 Pandemic," N Engl J Med 2020;382(18):e41, read in full from an Internet Archive copy of the NEJM page (nejm.org itself returned 403). Changes: (1) The quotation "far below standards" is not in the paper; the paper says the government bought ventilators "with capabilities far below the LTV 1200," the stockpile's main ventilator, which it says was itself judged to have important limitations. The sentence now quotes the paper, and the list of missing features (which read "high PEEP, precise tidal volume control, and advanced monitoring") now follows the paper's Table 2 and is attached, on the second read, to two of the models that table covers (pNeuton A-E and SAVe II; the second read also dropped "emergency" as a label for the pair, since the FDA list describes the pNeuton A-E as a continuous facility-use ventilator and only the SAVe II as a powered emergency ventilator) rather than to the LTV 1200: narrower PEEP ranges, fewer modes, and no monitoring of delivered flow or volume beside the portable critical care ventilator the review uses for comparison. (2) The claim that the EUA made it "impossible for clinicians to distinguish" critical care devices is not in either source; the paper says a couple of the stockpile purchases are on the EUA list with neither identified as a critical care ventilator and urges FDA to reconsider the definition "even to the uninitiated," and the FDA page says the umbrella EUA covers ventilators, modified anesthesia gas machines and modified positive-pressure breathing devices "collectively referred to as" ventilators. The sentence now says that. (3) "No binding performance tier standard exists ... and this gap remains unaddressed" is not a statement either source makes; the text now says the review describes no such standard, and adds the paper's remark that minimum requirements for acute respiratory failure ventilators had already been published. (4) "Approximately 170,000 full-featured ventilators" and "300,000+ critical care ventilators" are in neither source. The NEJM commentary gives 60,000 to 160,000 ventilators in the US "depending on whether those that have only partial functionality are included" and need "from several hundred thousand to as many as a million"; the paper calls the early predictions "inaccurate and often unrealistic" and reports 52,118 critical care ventilators in a hospital survey published in 2010. The text now carries the NEJM range with that caveat and the paper's judgment; "a shortfall that would affect tens of thousands of patients" was removed as unsourced, and "on a massive scale" was dropped. (5) "Ventilator shortages led to crisis standards of care, rationing" is contradicted: the paper says rationing "was discussed in the lay press and medical literature but was never necessary in the US," and that high mortality and regional surges "worked in concert to avoid a nationwide ventilator shortage." The text now says so, in the paper's own terms (the second read replaced "widely discussed" with where the paper says it was discussed). (6) "Home-use CPAP/BiPAP devices ... never designed for the ventilatory strategies required by severe ARDS" is softened to what the paper says: noninvasive bi-level ventilators were classified for minimal ventilatory support and "not intended for continuous life support," and anesthesia workstations are meant to be attended by anesthesia staff for cases under 24 hours (the FDA list confirms several bi-level devices are labeled for home use). (7) "No mandatory performance standard defining minimum capabilities for each tier" and "ISO 80601-2-12 ... compliance is not mandatory for all FDA-cleared devices" were not checkable for ordinary FDA clearance, which no source discusses; both sentences are now scoped to what the EUA record shows: the FDA list labels devices by type (critical care ventilator; continuous, minimal ventilatory support; emergency ventilator), Appendix A sets no minimum PEEP, tidal volume, FiO2 or mode requirement and asks sponsors to report modes, parameter ranges, alarms and monitored parameters and to declare conformance with its listed standards "as applicable" (the second read removed an "only" that left out the declarations), and ISO 80601-2-12 appears there with conformance requested "as applicable to the device." "Without performance tier differentiation" now reads that the authorization distinguishes device types by name but not by any performance tier. (8) "The failed Philips/BARDA stockpile contract" and "pre-pandemic procurement optimized for cost and quantity" are in neither source (Philips and BARDA are not mentioned). The sentence now carries the paper's own account of the 2020 purchases: a goal of 200,000 additional ventilators, 15 models, purchasers with "no medical expertise, much less ventilator expertise," about half of the purchases ill-suited to critical care, "over 70,000 ventilators ill-suited to critical care," and Table 2's per-device costs and counts (pNeuton A-E $7,600, about 50,000 bought; SAVe II $6,700, about 11,000; Hamilton T1 about $20,000; the table gives the two purchase prices as exact figures and the second read dropped the "about" before them). (9) "The EUA pathway has been wound down for ventilators" and the claim that declining political salience has reduced reform momentum: the FDA page says the public health emergency expired May 11, 2023, existing device EUAs remain in effect, and the declarations are to be terminated effective December 26, 2026; the paper says nothing about political attention. The text now reports the FDA page and the paper's own "lesson we should not relearn" line. Confirmed and left as written: the Source line (title, venue, year, DOI); that the EUA authorized modified anesthesia gas machines, home bi-level devices and emergency/transport ventilators; the "wrong-problem" reading in the notes above (the paper: "Initial efforts looked simply at acquiring as many ventilators as possible"). Not checked: the claim in "What Would Unlock Progress" and the entry points are proposals rather than sourced facts and were left alone; readers should know the paper's own advice to first-time ventilator builders is "don't!", which bears on the modular-prototype entry point. Titles unchanged. Genome Tags untouched.